Search results for: 'pfa pharmaceutical'

Frost & Sullivan identifies and defines the leading trends shaping the global pharmaceutical landscape in this analysis. The study period is 2021 2028, with 2023 as the base year and 2024 2028 as the forecast period. The geographic scope includes 5 regions: North America, Latin America (LATAM) and the Caribbean, Asia-Pacific (APAC), Europe, and the...

In 2024, the life science (LS) industry s focus on precision health will intensify. LS companies will augment their omics-based research capabilities and increasingly deploy AI and bioinformatics to discover personalized therapies. Partnerships between pharmaceutical companies and technology vendors will multiply, to support innovation in drug disc...

The pharmaceutical (pharma) industry is undergoing significant regulatory changes resulting from the European Green Deal and the Paris Agreement. These changes require pharma companies to adopt more environmentally sustainable practices. With the increasing demand for drugs globally, pharma R&D and manufacturing infrastructure has grown, leading to...

Per- and polyfluoroalkyl substances (PFAS) present substantial environmental and health risks. Their complex structure makes them resistant to natural breakdown and allows them to accumulate in living organisms, posing a potential health risk. Growing evidence of PFAS contamination in surface water, groundwater, wastewater, soil, and air is compell...

Changing regulatory landscapes significantly impact the chemical industry s evolution in technological advancement, product development, vertical integration, and consolidation activities. In a recent Frost & Sullivan report titled The Impact of Regulations on the Chemical Industry (PE52), we found that one of the key areas of regulation is in P...

This Frost & Sullivan report analyzes the global pharmaceutical excipients market, with a focus on key regional markets, including North America, Europe, Asia-Pacific, Latin America, and the Middle East and Africa (MEA). The report provides both qualitative and quantitative analyses of various segments, including oral dosage excipients, injectable ...

16 Aug 2016  |  North America  |  Market Research

Global Pharmaceutical Contract Manufacturing Organization (CMO) Market

Emerging Business Models Drive Transformation

Infographics

×

The key objective of this research is to provide in-depth knowledge of the major global pharmaceutical CMO market segments—active pharmaceutical ingredients (APIs) and intermediates; and finished dose formulations (FDFs), further segmented by solid, liquid and semi-solid, and injectable doses—and to understand the value chain from clinical to comme...

Scope of the report The research report includes the following segments: Product scope: Pharmaceutical Products Geographic scope: Ethiopia End-user scope: Pharmaceutical manufacturers, Pharmaceutical distributors, Healthcare providers, Contract Manufacturing Organisations (CMO) Revenue analysis and forecasts, drivers and restraints, business opp...

The global pharmaceutical market is projected to reach approximately $1.72 trillion in 2026, with large molecules driving most incremental growth while small molecules remain the sector’s cash flow base. The current growth cycle concentrates on cardiometabolic and oncology, led by GLP-1 platforms and antibody–drug conjugates (ADCs). Competitive adv...